Daniel J. O'Connor - 20 Feb 2025 Form 4 Insider Report for DiaMedica Therapeutics Inc. (DMAC)

Reporting relationship
Director
Issuer ticker
DMAC
Reported as of
20 Feb 2025
Net transaction value
$0
Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
24 Feb 2025, 17:06:33 UTC
Prior SEC filing
07 Mar 2024
Next SEC filing
03 Jun 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Amy E. Culbert, attorney-in-fact

Key filing fact

Daniel J. O'Connor filed Form 4 for DiaMedica Therapeutics Inc. (DMAC) on 24 Feb 2025.

Key facts

  • This page summarizes Daniel J. O'Connor's Form 4 filing for DiaMedica Therapeutics Inc. (DMAC).
  • 1 reported transaction and 1 derivative row are listed below.
  • Accepted by SEC: 24 Feb 2025, 17:06.

Change

  • Previous filing in this sequence was filed on 07 Mar 2024.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

DMAC holding

Voting Common Shares, no par value per share

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
0
Date
20 Feb 2025
Ownership
Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

DMAC transaction Derivative

Stock Option (right to buy)

Award

Transaction value
$0
Shares
+64,242
Change %
Price
$0.000000
Shares after
64,242
Date
20 Feb 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
64,242
Exercise price
$6.61
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Vests in 12 nearly equal quarterly installments over three years.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .